Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583

Journal of Clinical Oncology

Volumn 21, Issue 3, 2003, Pages 490-495

  Halabi, Susan ^a   Small, Eric J ^a   Hayes, Daniel F ^a   Vogelzang, Nicholas J ^a   Kantoff, Philip W ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; HYDROCORTISONE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL TIME; AGED; EVALUATION; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; RISK FACTOR; SURVIVAL; TUMOR EMBOLISM;

AGED; HUMANS; MALE; NEOPLASM CIRCULATING CELLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SURVIVAL;

EID: 0037315932     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.104     Document Type: Article

References (17)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. Ca: Cancer J Clin 51:15-36, 2001
2. Kantoff PW, Halabi S, Conaway MR, et al: Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182. J Clin Oncol 17:2506-2513, 1999
3. George DJ, Kantoff PW: Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 26:303-310, 1999
4. Kantoff PW, Halabi S, Farmer DA, et al: Prognostic significance of reverse transcriptase-polymerase chain reaction for prostate-specific antigen in men with hormone refractory prostate cancer. J Clin Oncol 19:3025-3028, 2001
5. Ghossein RA, Rosai J, Scher HI, et al: Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50:100-105, 1997
6. Katz AE, de Vries GM, Begg MD, et al: Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage patients with prostate cancer. Cancer 75:1642-1648, 1995
7. de la Taille A, Olsson CA, Buttyan R, et al: Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer 84:360-364, 1999
8. Mejean A, Vona G, Nalpas B, et al: Detection of circulating prostate-derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol 163:2022-2029, 2000
9. Ennis RD, Katz AE, de Vries GM, et al: Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Cancer 79:2402-2428, 1997
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Cox, DR: Regression models and life tables (with discussion). J Stat Soc B 74:187-220, 1972
12. Harrell, FE, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy and measuring and reducing errors. Stat Med 15:361-387, 1996
13. Harrell FE: Design: Splus function for biostatistical/epidemiological modeling, testing, estimation, validation, graphics, prediction, and typesetting by storing Enhanced model design attributes in the fit. 1994. Http:// www.statlib@lib.stat.cmu.edu
14. Ghossien RA, Scher HI, Gerald WI, et al: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: Clinical implications. J Clin Oncol 13:1195-1200, 1995
15. Vogelzang NJ, Crawford ED, Zietman A: Current clinical trial design issues in hormone-refractory prostate carcinoma. Cancer 82:2093-2101, 1998
16. Scher HI, Mazumdar M, Kelly WK: Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 88:1623-1634, 1996
17. Chen SH, George SL: The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 4:39-46, 1985